Day: February 24, 2022

PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and discuss recent business highlights. To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-9711 (international) and refer to conference ID 4137048. A live audio webcast of the event will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. The archived webcast will be available on Passage Bio’s website approximately two hours after the completion of the event and...

FRANKLIN, Ind., Feb. 24, 2022 (GLOBE NEWSWIRE) — IBC Advanced Alloys Corp. (TSX-V: IB; OTCQB: IAALF) (“IBC” or the “Company”) a leading beryllium and copper advanced alloys company, announced today that it will host a live webcast and conference call for investors and the general public on Wednesday, March 2, 2022, starting at 12 Noon Eastern. The webcast and conference call will feature Mark A. Smith, IBC CEO and Board Chairman, who will discuss the Company’s financial results for the quarter ended December 31, 2022, which are expected to be released on March 1, 2022, after market close. To register for the webinar and conference call, and receive instructions on how to call in or connect via the internet to the webinar, please go here: https://attendee.gotowebinar.com/register/138217828988545037 A recording of the webcast...

GREENWICH, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading provider of freight transportation services, has been awarded Carrier Partner of the Year for its less-than-truckload (LTL) performance by GlobalTranz Enterprises, LLC. This is the second year that XPO’s North American LTL business has been honored by GlobalTranz, a technology-driven, third-party logistics provider with extensive industry relationships. GlobalTranz determined its 2021 Carriers of the Year based on six criteria: financial performance, growth, customer service, collaboration, technological innovation and overall excellence. Mario Harik, acting president, less-than-truckload, and chief information officer of XPO Logistics, said, “Our partnership with GlobalTranz is based on delivering value for LTL shippers through technological...

CMX521 Significantly Reduced Lung Viral Titer and Clinical Symptoms in a SARS-CoV-2 Mouse Model DURHAM, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at the University of North Carolina at Chapel Hill, today announced that preclinical data from the Company’s CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research (ICAR) on Wednesday, March 23, 2022 from 12:15 – 1:00 pm PT. “While we focus on the advancement of our oncology pipeline and progress toward a TEMBEXA procurement agreement with BARDA, this collaboration with READDI allows us to efficiently evaluate our antiviral library to identify molecules that might have value to patients,” said Mike Sherman, Chief...

— Analysis from APeX-2 showed 94 percent attack-free days across all patients who completed 96 weeks of treatment — RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) showing sustained reductions in attack rates and improvement in quality of life (QoL) among patients living with HAE, regardless of their baseline attack rates and initial responses to ORLADEYO. The data are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held live in Phoenix, Arizona, and virtually, from February 25-28, 2022. “The long-term...

VISIONARY-MS Phase 2 blinded interim data suggest clinically relevant improvements in the modified MS Functional Composite for the study population through 48 weeks of treatmentREPAIR-MS Phase 2 clinical trial demonstrated improved brain energetic metabolism following CNM-Au8® treatmentSALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the presentation of updated blinded interim data from its VISIONARY-MS study and results from its REPAIR-MS study in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, taking place...

Not for distribution in the United States or to U.S. newswire services VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) — C2C Gold Corp. (CSE: CTOC; OTCQB:CTCGF) (the “Company” or “C2C”) announces a proposed non-brokered private placement of units and flow through units at a price of $0.18 per Unit and $0.22 per flow through unit for combined gross proceeds of up to $1,500,000. Each unit and flow through unit will consist of one common share and one-half of one share purchase warrant. Each whole warrant is exercisable into one non-flow through common share at a price of $0.25 per common share for a period of two years. The proceeds of the private placement will be used to fund exploration expenditures on the Company’s mineral exploration project and G&A expenses. The Company may pay finders’ fees in connection with...

PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) — Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference, which is taking place virtually March 7-9, 2022. Details are as follows:Fireside Chat Date: Monday, March 7, 2022Fireside Chat Time: 2:50-3:20 p.m. ESTWebcast link: https://wsw.com/webcast/cowen108/krys/2056797A webcast of the presentation will be available for 90 days and can be found on the Krystal Biotech website at http://ir.krystalbio.com/events-and-presentations/events. About Krystal BiotechKrystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform...